Article Information
History
- January 21, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Jesús Rufino2,1,
- Carlos Baquero3,1,
- Davide Frey4,1,
- Christin A. Glorioso5,1,
- Antonio Ortega6,1,
- Nina Reščič7,1,
- Julian Charles Roberts8,1,
- Rosa E. Lillo9,1,
- Raquel Menezes10,1,
- Jaya Prakash Champati2,1 and
- Antonio Fernádez Anta2,1,†
- 1CoronaSurveys Team, Spain
- 2IMDEA Networks Institute, Spain
- 3U. Porto & INESC TEC, Portugal
- 4Univ Rennes, IRISA, CNRS, Inria, 35042 Rennes, France
- 5Academics for the Future of Science, Inc. & U. of California San Francisco, USA
- 6U. Southern California, USA
- 7Jožef Stefan Institute, Department of Intelligent Systems, Ljubljana, Slovenia
- 8Gearu LTD, UK
- 9U. Carlos III de Madrid, Spain
- 10Centre of Mathematics of U. Minho, Portugal
- ↵†Corresponding author; email: antonio.fernandez{at}imdea.org
Posted January 21, 2022.
Using Survey Data to Estimate the Impact of the Omicron Variant on Vaccine Efficacy against COVID-19 Infection
